Respiratory Dysfunction in an Optineurin knock out ALS mouse model
Respiratory Dysfunction in an Optineurin knock out ALS mouse model
批准号:
9978360
负责人:
Mai ElMallah
金额:
$44.28万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-04-01 至 2022-09-30
关键词:
ALS patientsAddressAgeAge-YearsAmyotrophic Lateral SclerosisAnimalsAtaxiaAutomobile DrivingAutophagocytosisBiochemicalBiochemical PathwayBreathingCell DeathCell physiologyCellsChronicDefectDeglutitionDiagnosisDiseaseDisease ProgressionEmbryoEquilibriumEtiologyEvaluationEventExhibitsExposure toFibroblastsFunctional disorderFutureGenesGoalsHistologicHomeostasisHypoxiaImpaired cognitionImpairmentIn VitroInflammationKnock-outKnockout MiceLinkMeasuresMitochondriaMorphologyMotorMotor NeuronsMusMuscleMuscle WeaknessMutationNerveNerve DegenerationNeurobiologyNeurodegenerative DisordersNeuromuscular JunctionNeuronsOnset of illnessOutputOxygenParalysedPathologyPatientsPeripheralPlayProgressive DiseaseProteinsRegulationRespiration DisordersRespiratory FailureRespiratory InsufficiencyRespiratory MusclesRespiratory physiologyRiskRoleSecondary toSeriesStressTestingTherapeutic InterventionWorkawakeclinical careclinical investigationclinically relevantepidemiology studyequilibration disorderexperienceexperimental studyinnovationloss of functionmitochondrial autophagymotor impairmentmouse modelneurophysiologypre-clinicalprotein aggregationrelating to nervous systemrespiratorysuperoxide dismutase 1therapeutic targettoolventilation
中文摘要
点击翻译按钮获取中文摘要
英文摘要
7. PROJECT SUMMARY/ABSTRACT
Amyotrophic Lateral Sclerosis (ALS) is a devastating and fatal neurodegenerative disease with no current cure.
Focal weakness eventually progresses to global muscle weakness and paralysis, but the exact etiology of these
events remains unknown. Many patients die when they ultimately succumb to inadequate ventilation, hypoxia,
and respiratory failure. Recently, the gene for optineurin (OPTN) was found to be associated with
neurodegeneration in ALS. Patients with OPTN mutations show an onset of ALS from 30 to 60 years of age and
have a slowly progressive disease before they eventually die of respiratory failure. The etiology of OPTN
deficiency induced respiratory failure remains unknown and will be a focus of Aim 1 of this application. In addition,
in Aim 2, we will look at the impact of hypoxia (or low oxygen levels) on disease initiation and progression. In
ALS, impaired breathing due to progressive weakness of the respiratory muscles leads to chronic intermittent
hypoxia. However, prior to diagnosis, we propose that hypoxia may also play a role in triggering the disease
onset and exacerbating motor weakness in OPTN deficient patients. At the cellular level, hypoxia induces
mitochondrial degradation, activates autophagy and induces cell death. Interestingly, OPTN regulates
mitochondrial degradation, autophagy and cell death. Since OPTN is essential in regulating autophagy, we
propose that in the absence of OPTN, the effects of chronic intermittent hypoxia (CIH) will be amplified and will
result in protein aggregation and cellular disruption in respiratory motoneurons. This disruption will further
exacerbate breathing impairment. Thus, the fundamental hypothesis driving this proposal is that OPTN
deficiency impairs respiratory function, and exposure to CIH triggers early disease onset and
accelerates respiratory pathology. In order to test our hypothesis, we will use OPTN knock out mice (Optn-/-)
generated by Henry Tseng (co-I). Similar to pathology experienced by ALS patients, these mice exhibit deficits
in balance, coordination, and motor impairment that progressively deteriorates with age. Optn-/- mice provide an
important opportunity and an ideal tool to study stress-dependent mechanisms that exacerbate
neurodegeneration and respiratory function in ALS. Two specific aims will be accomplished using the Optn-/-
mouse model: Aim 1: To identify the impact of OPTN deficiency on respiratory function and respiratory
motoneurons, nerves, and muscle in ALS and Aim 2: To assess the impact of CIH on disease onset and
progression in OPTN deficiency. The proposed experiments address a comprehensive evaluation of respiratory
function including spontaneous breathing and respiratory nerve output, as well as biochemical and histological
assessment of respiratory motor units. This R21 proposal will combine the respiratory physiology and ALS
mouse model experience of the PI (ElMallah), with the neurobiology and optineurin experience of the co-I
(Tseng).
Project Summary/Abstract Page 1
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeted Therapy for Pompe Disease
-
批准号:10621268
-
项目类别:
-
资助金额:$34.54万
-
财政年份:2019
-
负责人:Mai ElMallah
-
依托单位:
Targeted Therapy for Pompe Disease
-
批准号:10202684
-
项目类别:
-
资助金额:$34.54万
-
财政年份:2019
-
负责人:Mai ElMallah
-
依托单位:
Targeted Therapy for Pompe Disease
-
批准号:10017695
-
项目类别:
-
资助金额:$34.84万
-
财政年份:2019
-
负责人:Mai ElMallah
-
依托单位:
Targeted Therapy for Pompe Disease
-
批准号:10402842
-
项目类别:
-
资助金额:$34.54万
-
财政年份:2019
-
负责人:Mai ElMallah
-
依托单位:
Duke Resident Physician-Scientist Program- NHLBI
-
批准号:10202710
-
项目类别:
-
资助金额:$33.94万
-
财政年份:2018
-
负责人:Mai ElMallah
-
依托单位:
Stimulating Access to Research in Residency (StARR) - NHLBI
-
批准号:10597856
-
项目类别:
-
资助金额:$31.48万
-
财政年份:2018
-
负责人:Mai ElMallah
-
依托单位:
Gene Therapy for Upper Airway and Respiratory Insufficiency in an ALS Mouse Model
-
批准号:9581552
-
项目类别:
-
资助金额:$20.94万
-
财政年份:2016
-
负责人:Mai ElMallah
-
依托单位:
Gene Therapy for Upper Airway and Respiratory Insufficiency in an ALS Mouse Model
-
批准号:9166838
-
项目类别:
-
资助金额:$23.78万
-
财政年份:2016
-
负责人:Mai ElMallah
-
依托单位:
Novel Approaches for Correcting Respiratory Insufficiency in Pompe Disease
-
批准号:9262981
-
项目类别:
-
资助金额:$3.77万
-
财政年份:2014
-
负责人:Mai ElMallah
-
依托单位:
Novel Approaches for Correcting Respiratory Insufficiency in Pompe Disease
-
批准号:8912059
-
项目类别:
-
资助金额:$10.77万
-
财政年份:2014
-
负责人:Mai ElMallah
-
依托单位:
Novel Approaches for Correcting Respiratory Insufficiency in Pompe Disease
-
批准号:9600122
-
项目类别:
-
资助金额:$12.45万
-
财政年份:2014
-
负责人:Mai ElMallah
-
依托单位:
Novel Approaches for Correcting Respiratory Insufficiency in Pompe Disease
-
批准号:8700662
-
项目类别:
-
资助金额:$1.4万
-
财政年份:2014
-
负责人:Mai ElMallah
-
依托单位:
海外基金